Trends and Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Bi‐National Registry Study Across Australia and New Zealand
ANZ Journal of Surgery · 2025
DOI: 10.1111/ans.70218 ↗Kurz gefasst
Fachartikel in der Zeitschrift ANZ Journal of Surgery, 2025. Verfasst von Ishraq Murshed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Surgery, Adelaide Medical School, Faculty of Health and Medical Sciences, Royal Adelaide Hospital, Adelaide, Australia. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Total Neoadjuvant Therapy (TNT) has significantly improved outcomes in locally advanced rectal cancer. Despite rising use and inclusion in international guidelines, adoption patterns in Australia and New Zealand (ANZ) remain unclear. This study determines bi‐national patterns and predictors of TNT utilisation over a 6‐year period.
Methods
A retrospective population‐based bi‐national registry cohort study analysed data from the ANZ Bowel Cancer Outcome Registry from 2018 to 2024. Patients diagnosed with primary locally advanced rectal cancer (LARC) and treated with standard neoadjuvant therapy (SNT), consisting of long‐course chemoradiotherapy or short‐course radiotherapy, or TNT were included. The primary outcome was the incidence of TNT utilisation over time and determining pre‐treatment predictive factors.
Results
Of 33 270 patient entries, 3234 eligible LARC patients were identified, with 706 (21.8%) receiving TNT and 2528 (78.2%) receiving SNT. TNT usage increased from 11% in 2018 to 41% in 2023. On multivariable logistic regression, independent factors associated with decreased TNT use were older age (OR: 0.978, 95% CI: 0.970–0.985, p < 0.001), absence of multidisciplinary team discussion (OR: 0.113, 95% CI: 0.027–0.472, p = 0.003) and private health insurance (OR: 0.619, 95% CI: 0.441–0.869, p = 0.006). Factors associated with increased TNT use were clinical T4 tumours (OR: 2.020, 95% CI: 1.245–3.280, p = 0.004), node‐positive status (OR: 1.481, 95% CI: 1.118–1.964, p = 0.006) and diagnosis during the years 2019–2023 ( p < 0.05 for all).
Conclusions
TNT is increasingly used in surgical rectal cancer patients captured in the BCOR in ANZ. This study provides a baseline for future benchmarking patterns of rectal cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Discipline of Surgery, Adelaide Medical School, Faculty of Health and Medical Sciences, Royal Adelaide Hospital, Adelaide, Australia.
- Colorectal Unit, Department of Surgery, University of Adelaide, Adelaide, South Australia, Australia.
ORCID-Profile: Ishraq Murshed, Sergei Bedrikovetski, Zachary Bunjo, Hidde M Kroon, Tarik Sammour
Zitieren
APA
Murshed, I., Bedrikovetski, S., Bunjo, Z., Kroon, H. M., Thomas, M., & Sammour, T. (2025). Trends and Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Bi‐National Registry Study Across Australia and New Zealand. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70218
Vancouver
Murshed I, Bedrikovetski S, Bunjo Z, Kroon HM, Thomas M, Sammour T. Trends and Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Bi‐National Registry Study Across Australia and New Zealand. ANZ Journal of Surgery. 2025. doi:10.1111/ans.70218
BibTeX
@article{Murshed2025,
author = {Murshed, Ishraq and Bedrikovetski, Sergei and Bunjo, Zachary and Kroon, Hidde M and Thomas, Michelle and Sammour, Tarik},
title = {Trends and Predictors of Total Neoadjuvant Therapy in Rectal Cancer: A Bi‐National Registry Study Across Australia and New Zealand},
journal = {ANZ Journal of Surgery},
year = {2025},
doi = {10.1111/ans.70218}
}
EUVIMED